title: Comparison of the efficacy and tolerability of gefitinib with pemetrexed maintenance after first-line platinum-based doublet chemotherapy in advanced lung adenocarcinoma: single-center experience.
abstract: OBJECTIVE
  Both gefitinib and pemetrexed maintenance were effective therapies for advanced lung adenocarcinoma, but which is better is unclear. For patients with advanced lung adenocarcinoma, we have no idea whether we should choose gefitinib or pemetrexed maintenance in clinical practice. Here, we assessed the efficacy and tolerability of gefitinib versus pemetrexed maintenance in these patients.
  
  
  METHODS
  A total of 101 patients were identified and divided into gefitinib (n=53) or pemetrexed (n=48) maintenance. Epidermal growth factor receptor (EGFR) status of tumors was analyzed in 67 patients. Disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) were compared between the two groups.
  
  
  RESULTS
  The results showed that DCR (79.2% vs 75%,P=0.642) was similar between gefitinib and pemetrexed groups. The PFS of gefitinib was significantly longer than that of pemetrexed (8 months vs 5.4 months, hazard ratio [HR]: 0.520, 95% confidence interval [CI]: 0.341-0.791,P=0.002); however, the OS was similar (19.9 months vs 18.8 months, HR: 1.006, 95% CI: 0.664-1.525,P=0.977). In EGFR mutation-positive patients, PFS was significantly longer in gefitinib (12 months vs 5.4 months; HR: 0.158, 95% CI: 0.074-0.333,P<0.001), whereas in EGFR wild-type subgroup gefitinib had a significantly shorter PFS than that by pemetrexed (2.5 months vs 5 months; HR: 2.822, 95% CI: 1.137-7.005,P=0.025). Cox multivariate regression analysis of PFS for overall population showed that smoking status (P=0.001) and maintenance regimens (P=0.013) were independent prognostic factors for PFS. Both gefitinib and pemetrexed were well tolerated.
  
  
  CONCLUSIONS
  Gefitinib compared with pemetrexed as maintenance therapy had a significantly longer PFS and a similar OS with good tolerability in patients with advanced lung adenocarcinoma. Moreover, for EGFR mutation-positive patients, gefitinib maintenance had a significantly longer PFS; however, pemetrexed maintenance was considered more effective for EGFR wild-type patients.
authors: Department of Oncology, Panyu Central Hospital; Cancer Institute of Panyu.
authors: Liping
authors: L
authors: Lin
authors: School of Nursing, Sun Yat-sen University, Guangzhou, People's Republic of China.
authors: Juanjuan
authors: J
authors: Zhao
authors: Department of Oncology, Panyu Central Hospital; Cancer Institute of Panyu.
authors: Jiazhu
authors: J
authors: Hu
authors: Department of Oncology, Panyu Central Hospital; Cancer Institute of Panyu.
authors: Fuxi
authors: F
authors: Huang
authors: Department of Oncology, Panyu Central Hospital; Cancer Institute of Panyu.
authors: Jianjun
authors: J
authors: Han
authors: Department of Oncology, Panyu Central Hospital; Cancer Institute of Panyu.
authors: Yan
authors: Y
authors: He
authors: Department of Oncology, Panyu Central Hospital; Cancer Institute of Panyu.
authors: Xiaolong
authors: X
authors: Cao
keywords: gefitinib; lung adenocarcinoma; maintenance therapy; pemetrexed